Search results
Showing 1 to 2 of 2 results for ta616
Cladribine for treating relapsing–remitting multiple sclerosis (TA616)
Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis in adults.
Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)
This guidance has been updated and replaced by NICE technology appraisal guidance 616.